Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Myelodysplastic Syndrome

Aliases
Myelodysplastic Syndrome Post Cytotoxic Therapy, Previously Treated Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome

215 clinical trials

233 products

37 drugs

Product
RVU120(SEL120)
Clinical trial
A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.
Status: Completed, Estimated PCD: 2023-05-23
Product
SLN124
Product
EPZ-5676
Product
Placebo
Clinical trial
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies
Status: Completed, Estimated PCD: 2015-11-01
Product
Azacitidine
Product
Glasdegib
Clinical trial
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2025-08-01
Product
CLN-049
Clinical trial
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
Status: Active (not recruiting), Estimated PCD: 2025-02-14
Product
Venetoclax
Clinical trial
A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Terminated, Estimated PCD: 2023-05-09
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Status: Completed, Estimated PCD: 2019-01-25
Product
Lemzoparlimab
Product
fadraciclib
Product
Oral Azacitidine
Clinical trial
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2024-10-01
Product
Tamibarotene
Product
Daratumumab
Clinical trial
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Status: Completed, Estimated PCD: 2020-01-29
Product
PF-04449913
Product
LP-001
Clinical trial
A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of LP-001 Injection in Healthy Subjects Following Single and Multiple Doses
Status: Active (not recruiting), Estimated PCD: 2024-01-02
Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
Ruxolitinib
Product
BTX-A51
Clinical trial
A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Alone and in Combination With Azacitidine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Pelabresib
Clinical trial
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
BLEX 404
Product
APG-115
Clinical trial
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia With or Without NPM1 Mutation (RIVER-52)
Status: Recruiting, Estimated PCD: 2026-02-01
Product
RVU120
Product
NC525
Clinical trial
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Status: Recruiting, Estimated PCD: 2025-05-01
Product
VIP943
Clinical trial
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
5-azacitidine
Clinical trial
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-05-30
Product
INCB057643
Product
NEXI-001 T Cells
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Status: Recruiting, Estimated PCD: 2025-06-30
Product
CCS1477
Product
Dexamethasone
Product
Pomalidomide
Clinical trial
An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Fludarabine
Product
Treosulfan
Clinical trial
Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia
Status: Recruiting, Estimated PCD: 2028-12-30
Product
Luspatercept
Clinical trial
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Standard-of-Care
Product
Orca-T
Product
MGTA-145
Product
Plerixafor
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Terminated, Estimated PCD: 2021-09-14
Product
KHK2823
Clinical trial
Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Status: Terminated, Estimated PCD: 2019-05-10
Clinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Product
APL-4098
Product
MBG453
Clinical trial
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Status: Recruiting, Estimated PCD: 2023-09-08
Product
Decitabine
Product
INQOVI
Product
HDM201
Clinical trial
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Product
ATG-016
Clinical trial
A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
Status: Terminated, Estimated PCD: 2023-09-19
Product
Guadecitabine
Clinical trial
A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)
Status: Completed, Estimated PCD: 2009-11-30
Product
VCL-CB01
Clinical trial
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Status: Terminated, Estimated PCD: 2021-10-04
Clinical trial
A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects With Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
JSP191
Product
AMG 330
Product
SyB L-1101
Product
FG-4592
Clinical trial
A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-01-11
Clinical trial
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies
Status: Terminated, Estimated PCD: 2022-01-09
Clinical trial
A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2011-09-01
Product
bomedemstat
Clinical trial
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies
Status: Completed, Estimated PCD: 2018-10-30
Product
tretinoin
Clinical trial
Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2015-02-01
Product
SyB C-1101
Product
LY3410738
Clinical trial
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Status: Active (not recruiting), Estimated PCD: 2023-07-03
Clinical trial
Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2014-11-01
Product
ASTX030
Clinical trial
A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Study to Evaluate the Pharmacokinetics of ASTX030 in Patients With Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2024-11-01
Product
decitabine
Clinical trial
An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary Disease
Status: Withdrawn, Estimated PCD: 2023-08-31
Product
Decitabine + Cedazuridine
Product
sabatolimab
Clinical trial
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
Status: Completed, Estimated PCD: 2023-05-08
Product
venetoclax
Product
Bisantrene Dihydrochloride
Product
Cytarabine
Clinical trial
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
3D189
Product
NiCord
Clinical trial
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Status: Terminated, Estimated PCD: 2020-06-01
Clinical trial
A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Product
BPX-501
Product
Rimiducid
Clinical trial
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2021-04-29
Product
Selinexor
Product
BPX-701
Clinical trial
A Phase 2, Open-Label, Single Arm Study Evaluating the Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Erythropoietin (EPO)-Refractory Lower-Risk Myelodysplastic Syndrome (MDS)
Status: Withdrawn, Estimated PCD: 2017-12-01
Product
CG200745
Product
azacitidine
Clinical trial
A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal Melanoma
Status: Terminated, Estimated PCD: 2019-07-19
Clinical trial
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2023-04-21
Clinical trial
A Study to Evaluate Pharmcokinetics, Pharmacodynamics , Efficacy and Safety of 6MW3211 Monotherapy and in Combination With Azacitidine(AZA) or AZA Plus Venetoclax(VEN) in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2024-06-01
Product
ASP7517
Product
AK117
Clinical trial
A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Phase 1, Open Label, Multicentre Clinical Trial of SyB C-1101 in Combination With Azacytidine in Patients With Myelodysplastic Syndrome
Status: Withdrawn, Estimated PCD: 2017-06-01
Product
SyB C-1101 and Azacytidine
Product
6MW3211
Clinical trial
Multi-center, Open-label, Phase I Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2019-05-28
Clinical trial
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Status: Terminated, Estimated PCD: 2019-07-25
Product
AMG 397
Clinical trial
A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes With Excess Blasts (MDS-EB), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Recruiting, Estimated PCD: 2026-10-03
Product
Clofarabine
Clinical trial
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Edetate Calcium Disodium
Product
Succimer
Clinical trial
Personalized NK Cell Therapy in CBT
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Anti-Thymocyte Globulin
Product
Busulfan
Drug
fludarabine
Drug
Melphalan
Clinical trial
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Status: Recruiting, Estimated PCD: 2029-05-15
Product
Daunorubicin
Product
Gilteritinib
Product
Liposome-encapsulated Daunorubicin-Cytarabine
Clinical trial
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2023-01-13
Product
Cyclosporine
Clinical trial
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
Imetelstat
Product
Leucovorin Calcium
Product
Methotrexate
Clinical trial
Phase 2a Study of Adding Ruxolitinib With Tacrolimus/Methotrexate Regimen for Graft-versus-Host Disease Prophylaxis in Myeloablative Conditioning Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients
Status: Not yet recruiting, Estimated PCD: 2027-10-31
Product
Tacrolimus
Clinical trial
Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Eltanexor
Clinical trial
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
Status: Recruiting, Estimated PCD: 2025-01-30
Product
Decitabine and Cedazuridine
Clinical trial
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
Status: Recruiting, Estimated PCD: 2025-06-01
Drug
Ivosidenib
Clinical trial
Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Status: Completed, Estimated PCD: 2022-07-12
Product
Prexasertib
Product
Pevonedistat
Clinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
mFOLFOX6
Product
Uproleselan
Clinical trial
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
Status: Active (not recruiting), Estimated PCD: 2023-08-28
Drug
cyclophosphamide
Product
Mycophenolate Mofetil
Clinical trial
Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Status: Recruiting, Estimated PCD: 2025-09-11
Product
Seclidemstat
Clinical trial
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2027-10-01
Product
Cladribine
Product
CLLDAC Regimen
Clinical trial
Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-03-19
Drug
N-803
Clinical trial
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2028-11-11
Clinical trial
Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Not yet recruiting, Estimated PCD: 2027-02-24
Product
Sirolimus
Clinical trial
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-10-08
Product
Dilanubicel
Product
Cyclophosphamide
Product
Thiotepa
Clinical trial
An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-Azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (> 65 Years) Patients
Status: Completed, Estimated PCD: 2023-10-09
Product
Ipilimumab
Drug
T-VEC
Clinical trial
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Zoledronate
Clinical trial
A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Donor Lymphocytes
Product
Mesna
Drug
Filgrastim
Product
Mycophenolate mofetil
Product
Total Body Irradiation
Clinical trial
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Mycophenolate
Clinical trial
Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Akt/ERK Inhibitor ONC201
Product
Idarubicin
Clinical trial
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Rabbit ATG
Product
Peripheral blood stem cell
Clinical trial
An Open-Label Phase 1/2 Multi-Arm Study of DS-1594b as a Single-Agent and in Combination With Azacitidine and Venetoclax or Mini-HCVD for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-11-08
Product
DS-1594b
Clinical trial
A Reduced Intensity Conditioning With Clofarabine Antithymocyte Globulin and Total Lymphoid Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases
Status: Completed, Estimated PCD: 2018-12-14
Clinical trial
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2025-12-01
Product
cyclosporine
Clinical trial
A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-04-04
Product
Gemtuzumab Ozogamicin
Clinical trial
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
Status: Recruiting, Estimated PCD: 2025-09-30
Product
Allogeneic Natural Killer Cell Line NK-92
Clinical trial
Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
Status: Completed, Estimated PCD: 2022-09-20
Product
Ibrutinib
Clinical trial
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Belinostat
Drug
Varlilumab
Product
Pegfilgrastim
Clinical trial
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2025-05-31
Product
SL-401
Clinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
Status: Not yet recruiting, Estimated PCD: 2028-02-01
Product
ATG
Clinical trial
Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myeloid Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Product
Conditioning Regimen
Clinical trial
Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission
Status: Active (not recruiting), Estimated PCD: 2019-12-27
Product
clofarabine
Product
melphalan
Drug
tacrolimus
Drug
sirolimus
Clinical trial
Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia
Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
A Phase I/II, Open-label, Single Arm, Multicenter Dose-finding Study Assess the Safety and Preliminary Efficacy of Oral Azacitidine CC-486 (ONUREG) in Combination With Venetoclax (VENCLYXTO) in Previously Untreated Higher-risk Myelodysplastic Syndromes Ineligible for Allogenic Transplantation
Status: Recruiting, Estimated PCD: 2025-11-01
Product
Onureg + Venetoclax
Product
Granulocyte Colony-Stimulating Factor
Clinical trial
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Decitabine/cedazuridine
Product
Triple Intrathecal Chemotherapy
Clinical trial
Phase I Open-Label Study of Fostamatinib, a SYK Inhibitor, in Patients With Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Fostamatinib
Clinical trial
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Status: Terminated, Estimated PCD: 2022-06-24
Product
Haplo-identical cells
Product
Umbilical Cord Blood Unit
Clinical trial
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies
Status: Completed, Estimated PCD: 2017-03-23
Product
INCB018424
Clinical trial
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Product
BMS-986497
Clinical trial
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Product
Itacitinib
Product
Actinium Ac 225-DOTA-Daratumumab
Product
Indium In 111-DOTA-Daratumumab
Clinical trial
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2017-04-01
Product
Lenalidomide
Drug
bortezomib
Product
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Product
Cemiplimab
Clinical trial
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment
Status: Completed, Estimated PCD: 2022-09-20
Clinical trial
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-10-01
Product
LP-118
Clinical trial
A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) With Azacitidine as Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS
Status: , Estimated PCD: 2025-05-03
Clinical trial
A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting, Estimated PCD: 2026-07-20
Product
Magrolimab
Product
Mitoxantrone
Clinical trial
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Status: , Estimated PCD: 2027-10-16
Product
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Product
Antithymocyte Globulin
Drug
busulfan
Drug
mycophenolate mofetil
Clinical trial
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Asparaginase
Product
Asparaginase Erwinia chrysanthemi
Product
Etoposide
Product
Thioguanine
Clinical trial
A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Young Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2023-04-12
Product
Reduced-Intensity Conditioning Regimen
Product
Myeloablative Conditioning Regimen
Clinical trial
Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2024-12-13
Product
Basiliximab
Product
Indium In 111-DOTA-Basiliximab
Product
Palifermin
Product
Yttrium Y 90 Basiliximab
Clinical trial
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-13
Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2030-04-07
Product
Letermovir
Clinical trial
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Status: Recruiting, Estimated PCD: 2024-05-31
Drug
Ceralasertib
Clinical trial
Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Status: Terminated, Estimated PCD: 2020-12-10
Product
Abemaciclib
Product
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Clinical trial
A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
RAD001
Product
PKC412
Product
Afatinib
Drug
Atezolizumab
Product
Bortezomib
Product
Dabrafenib
Clinical trial
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Pivekimab
Clinical trial
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Midostaurin
Product
Cabozantinib
Clinical trial
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: , Estimated PCD: 2015-02-20
Product
Tipifarnib
Drug
UTD1
Clinical trial
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Dexrazoxane
Clinical trial
Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease
Status: Completed, Estimated PCD: 2020-10-09
Drug
methotrexate
Clinical trial
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Dasatinib
Product
Darolutamide
Drug
R-CHOP
Clinical trial
Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2023-02-07
Clinical trial
NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Status: Completed, Estimated PCD: 2022-05-10
Drug
IL-2
Product
Quizartinib
Drug
AN0025
Product
Enasidenib
Clinical trial
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2021-09-30
Drug
Docetaxel
Product
Hydrocortisone
Clinical trial
CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2011-11-01
Product
Allodepleted T Cells
Clinical trial
Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals"
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Methylprednisolone
Clinical trial
A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Posaconazole
Product
Prednisone
Clinical trial
Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source
Status: Recruiting, Estimated PCD: 2024-04-28
Drug
Vincristine
Product
Voriconazole
Clinical trial
Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies
Status: Terminated, Estimated PCD: 2011-05-17
Drug
etoposide
Clinical trial
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Active (not recruiting), Estimated PCD: 2019-07-08
Product
Epoetin Alfa
Clinical trial
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-10-11
Product
Copanlisib
Clinical trial
Phase II Study of the Targeted Mutant IDH2 Inhibitor Enasidenib in Combination With Azacitidine for Relapsed/Refractory AML
Status: Recruiting, Estimated PCD: 2025-09-20
Clinical trial
A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)
Status: Completed, Estimated PCD: 2023-03-30
Product
Abiraterone
Clinical trial
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Olaparib
Product
Bicalutamide
Product
Cabazitaxel
Product
Dacomitinib
Clinical trial
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Canakinumab
Product
Cytokine-treated Veto Cells
Drug
Celecoxib
Product
Cobimetinib
Product
T Cell-Depleted Donor Lymphocyte Infusion
Clinical trial
A Phase I/II Study of Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Haploidentical and Cord Blood Stem Cell Transplantation
Status: Completed, Estimated PCD: 2023-03-01
Product
Recombinant Interleukin-7
Clinical trial
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Status: Terminated, Estimated PCD: 2022-11-11
Clinical trial
CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2022-01-22
Product
Allogeneic CD56-positive CD3-negative Natural Killer Cells
Clinical trial
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related Changes
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Pomalidomide
Drug
Entrectinib
Product
Enzalutamide
Clinical trial
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Active (not recruiting), Estimated PCD: 2029-05-01
Product
iCaspase9-transduced T cells
Product
AP1903
Clinical trial
A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Vorinostat
Drug
Erlotinib
Clinical trial
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Product
Fludarabine and Busulfan + Low Dose Total Body Irradiation
Clinical trial
A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation
Status: Completed, Estimated PCD: 2022-02-28
Product
Natural Killer Cell Therapy
Clinical trial
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy
Status: Completed, Estimated PCD: 2022-06-07
Product
Trivalent Influenza Vaccine
Clinical trial
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Status: Active (not recruiting), Estimated PCD: 2021-05-28
Clinical trial
Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-01-25
Product
Low dose Cyclophosphamide
Clinical trial
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Drug
alemtuzumab
Clinical trial
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
LHRH agonist
Product
Degarelix
Clinical trial
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Active (not recruiting), Estimated PCD: 2015-06-01
Drug
lenalidomide
Clinical trial
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Anti-thymocyte globulin
Product
Blinatumomab
Product
HPC,A
Clinical trial
Preemptive Infusion of Donor Lymphocytes Depleted of TCR (Alpha-beta) + T Cells and CD19+ B Cells Following Allogeneic Stem Cell Transplantation
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Cellular therapy
Clinical trial
A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-02-09
Product
Trametinib
Clinical trial
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Status: Active (not recruiting), Estimated PCD: 2023-02-22
Product
Umbilical cord blood cell infusion
Clinical trial
A Phase 1 Study of AMG 176 as Monotherapy and in Combination With Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Status: Completed, Estimated PCD: 2023-12-19
Product
AMG 176
Clinical trial
Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.
Status: Completed, Estimated PCD: 2022-06-06
Clinical trial
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Status: Completed, Estimated PCD: 2021-06-01
Product
Natural Killer Cells
Product
ALT803
Clinical trial
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Status: Completed, Estimated PCD: 2023-02-13
Clinical trial
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With High-risk MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS
Status: Active (not recruiting), Estimated PCD: 2021-11-06
Clinical trial
Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation
Status: Terminated, Estimated PCD: 2016-10-01
Clinical trial
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Hematopoietic Cell Transplantation Conditioning Regimen
Product
Stem Cell Mobilization Therapy
Clinical trial
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Product
Peripheral Blood Stem Cell
Clinical trial
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2023-08-21
Clinical trial
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Prospective Trial of Revlimid® in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2022-09-01
Product
Revlimid
Clinical trial
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Cirtuvivint
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Status: Completed, Estimated PCD: 2016-08-01
Drug
Plerixafor
Clinical trial
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2018-03-04
Product
CMVpp65-A*0201
Clinical trial
A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
Status: Not yet recruiting, Estimated PCD: 2024-12-11
Product
TAK-243
Clinical trial
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Status: Terminated, Estimated PCD: 2020-08-17
Product
Fludarabine and Busulfan plus/minus Total Body Irradiation
Clinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Status: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic Cells
Clinical trial
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study
Status: Completed, Estimated PCD: 2022-02-03
Clinical trial
Single Arm Prospective Open Label Pilot Study Evaluating Short-Term Safety and Efficacy of Romiplostim in Children With Inherited and Acquired Disorders of Hematopoietic Failure
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Romiplostim
Product
Sorafenib
Clinical trial
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Status: Active (not recruiting), Estimated PCD: 2022-10-01
Product
Entinostat
Clinical trial
An Open-Label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
Status: Terminated, Estimated PCD: 2022-11-21
Clinical trial
Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2023-03-16
Product
CB-839
Clinical trial
Venetoclax + Azacytidine Followed by Modified BUCY Conditioning Regimen for High-risk Myelodysplastic Syndromes (MDS) and High-risk or Relapsed/Refractory Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Status: Recruiting, Estimated PCD: 2025-01-20
Product
VEN+AZA
Clinical trial
Phase Ib/II Study of Omacetaxine and Venetoclax for Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Omacetaxine Mepesuccinate
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Status: Completed, Estimated PCD: 2018-04-12
Drug
Motixafortide
Clinical trial
A Randomized Phase II Study Evaluating the Efficacy of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Hyperbaric oxygen
Clinical trial
A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Status: Recruiting, Estimated PCD: 2025-05-11
Clinical trial
An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Drug
CPX-351
Product
Busulphan
Clinical trial
Phase I/II Study of Azacitidine in Combination With Quizartinib for Patients With Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms With FLT3 or CBL Mutations
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-08-11
Drug
rapamycin
Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2018-01-25
Clinical trial
Use of T-allo10 Cell Infusions Combined With Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-07-01
Product
T-allo10
Clinical trial
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML
Status: Recruiting, Estimated PCD: 2025-12-31
Product
CMGV
Clinical trial
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-01-31
Product
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
Product
Mycophenolate Sodium
Clinical trial
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome
Status: Recruiting, Estimated PCD: 2025-04-28
Product
Omidubicel
Clinical trial
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Open-label Pilot Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Myeloproliferative Neoplasms.
Status: Terminated, Estimated PCD: 2022-11-03
Product
ADCT-301
Clinical trial
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Product
EBX-102
Clinical trial
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cedazuridine
Clinical trial
Phase 2 Study of SGI-110 in Patients With Higher Risk MDS
Status: Active (not recruiting), Estimated PCD: 2024-11-04
Clinical trial
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Melphalan
Clinical trial
Combination of Nivolumab and Ipilimumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Drug
Lurbinectedin
Clinical trial
A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Not yet recruiting, Estimated PCD: 2027-02-17
Drug
Regorafenib